Pfizer-BioNTech vaccine found to be effective against Covid variant discovered in the UK
- The variant, known as B.1.1.7., has an unusually high number of mutations and is associated with more efficient and rapid transmission.
- It had led to concerns about the effectiveness of Covid vaccines against it.
- Authors of the study warned the rapid spread of Covid variants worldwide required “continuous monitoring of the significance of changes for maintained protection by currently authorized vaccines.”
-
LONDON — The coronavirus vaccine developed by Pfizer-BioNTech is likely to be just as effective against a highly transmissible mutant strain of the virus that was first discovered in the U.K., according to a study by the two companies.
The variant, known as B.1.1.7., was estimated to have first emerged in the U.K. in September 2020. It has an unusually high number of mutations and is associated with more efficient and rapid transmission.
The characteristics of the variant had led to concerns about the effectiveness of Covid vaccines against it.
However, research published on preprint server bioRxiv showed “no biologically significant difference in neutralization activity” between the laboratory tests on B.1.1.7 and the original strain of the coronavirus.
The study, which has not yet been peer-reviewed, found that all of the mutations associated with the newly-discovered variant were neutralized by antibodies in the blood of 16 participants who had previously been given the vaccine.
Half of the participants were aged between 18 and 55 and the other half were aged between 56 and 85.
Authors of the study warned the rapid spread of Covid variants worldwide required “continuous monitoring of the significance of changes for maintained protection by currently authorized vaccines.”